(VIANEWS) – The NASDAQ opens in less than one hour and NeuroMetrix‘s pre-market value is already 4.76% down.
NeuroMetrix’s last close was $1.88, 68.08% below its 52-week high of $5.89.
The last session, NASDAQ finished with NeuroMetrix (NURO) jumping 3.3% to $1.88. NASDAQ jumped 2.01% to $11,364.41, after two consecutive sessions in a row of gains, on what was an all-around positive trend exchanging session.
NeuroMetrix, Inc. is a healthcare company that designs, builds, and markets medical devices to stimulate and analyze nerve responses for therapeutic and diagnostic purposes. It operates in North America, Europe, Japan, China, Japan, China, Mexico, China, Japan, China, China, Middle East, and Mexico. DPNCheck is a nerve conduction test used for diagnosing peripheral neuropathy, including diabetic peripheral nervepathy. Quell provides symptomatic relief, and chronic pain management. The ADVANCE platform, which allows for nerve conduction studies, is the company’s main product. It sells its products to primary care doctors, occupational health, primary and internal medicine specialists, as well as primary care physicians. NeuroMetrix, Inc., was founded in 1996. It is located in Woburn, Massachusetts.
Earnings per Share
NeuroMetrix’s trailing twelve-month EPS is $-0.42.
For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -20.47%.
More news about NeuroMetrix (NURO).